BTBogdan Toia

Bogdan Toia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bogdan Toia has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Natural history of artificial urinary sphincter cuff erosion in males: Experience from two tertiary centres in the United Kingdom

    by Loufopoulos Ioannis, Pace Keith, Toia Bogdan, Kapriniotis Konstantinos, Papaefstathiou Efstathios, Newman Thomas, Barratt Rachel, Nobrega Richard, Noah Anthony, Gresty Helena, et al.

    Objectives: This study aimed to describe the natural history of urethral cuff erosion (UCE) following artificial urinary sphincter (AUS) implantation, including the incidence of urethral stricture and fistula formation, and the outcomes of salvage AUS reimplantation, based on the experience of two UK tertiary centres. Material and methods: Data collected prospectively from 2016 to 2024 was analysed retrospectively. Demographics, characteristics and outcomes of AUS re‐implantation were analysed. Results: A total of 273 AUS implantation were performed during the study period. Fifty had device explantation for UCE. Median age at explantation was 73 years. Median time from implantation to erosion was 32 months. About 12% had a history of neurogenic bladder and 58% pelvic irradiation. The most significant cause of acute erosion was traumatic catheterisation (44%). Following explantation, nine developed urethral stricture (18%), while five patients had urethro‐cutaneous fistulae (10%). Twelve individuals underwent salvage AUS re‐implantation with 6 (50%) requiring further explantation (50%) within 8 months. Of the remaining 38 patients, 17 continued with pad use alone and 21 underwent alternative conservative management including long‐term catheterisation, convene drainage, penile clamp or urethral bulking. Four patients (8%) ultimately required urinary diversion, two following primary explantation and two following failed salvage reimplantation. Conclusion: Overall, 18% of males having AUS implantation had UCE and explantation of the device. The vast majority of them had a history of pelvic irradiation or catheterisation for stricture disease (76%). The main risk for UCE was traumatic catheterisation. About 18% of explanted cases developed urethral stricture and 10% urethra‐cutaneous fistulae. Only 24% of these patients had attempted salvage AUS re‐implantation, with one half resulting in further early UCE/infection and removal.

  • Open Access

    The developing field of meshology - what is new in the management of mesh complications in female incontinence and prolapse - a systematic review of outcomes.

    by Bogdan Toia, Amna Butt, Rachel Barratt, Anthony O Noah, Mahreen H Pakzad, Richard P Nobrega, Jeremy L Ockrim, Helena C M Gresty, Tamsin J Greenwell

    Women having mesh procedures may require revision surgery in the long term due to complications. In the past decade, the field has evolved, moving towards specialist mesh centres. This systematic review analyses indications for treatment, whether complete mesh removal was achieved and treatment outcomes for delayed mesh complications. Fifty-six studies involving 4480 patients were identified from 2015 to 2025, to our knowledge, making this the largest systematic review of mesh complications in the modern era. Pain is the most common reason for seeking treatment for mesh complications and is present in up to 49-68% of women. Isolated surgical treatment for pain in the absence of anatomical abnormalities has poorer outcomes and often requires a holistic approach with specialist pain input. Asymptomatic vaginal exposure of under 1 cm can be treated with topical oestrogen with excellent success rates in selected patients. Endoscopic treatment for urethral extrusion has a 3% risk of urethrovaginal fistula. The risk of de novo incontinence is higher when the sub-urethral component of the mesh is removed compared to mesh arms (odds ratio 10.7). In large series, 15.6% of patients stayed in hospital for over 2 days after mesh removal, with a 2.8-13.7% incidence of >Clavien 3 complications. Robotic mesh removal surgery is an emerging approach and may play an important role, particularly when additional procedures are required, such as ureteric reconstruction and colposuspension.

  • What Evidence Do We Need From Objective and Subjective Outcomes in Order to Recommend Specific Operative Procedures for Men to Relieve BPO and Women With SUI? ICI‐RS 2025

    by Jeremy Ockrim, Phil Toozs‐Hobson, Chris Chapple, Vik Khullar, Kevin Rademakers, Sachin Malde, Bogdan Toia, Efstathios Papaefstathiou, Nikki Cotterill, Paul Abrams

    Aim: Metrics used to evaluate meaningful clinical outcomes have long been a matter of controversy, particularly where there is no defined objective cure and patient‐reported metrics (PROMs) are utilised as objective measures of subjective phenomena. The ICI‐RS 2025 think tank discussed the relative merits of objective and subjective outcomes in clinical trials. Methods: A review of medical literature in four key areas; hard metrics versus PROMs assessment of Minimally Invasive Surgical Treatments for Bladder Outflow Obstruction, for Stress Urinary Incontinence, and their use in current registries and databases were debated. Limitations of trial design were highlighted and proposals for further reporting, steering groups and guidance panels suggested. Results: It is yet to be fully understood how objective data and PROMs weigh bias and variability. Longitudinal study for objective and subjective metrics is required. Qualitative study with benchmarking may allow future studies to allow patients to set their own goals and develop more nuanced, patient‐defined PROMs. Databases incorporating core metrics, specialist assessments and regression analysis may have utility to create composite algorithms into unified scoring systems. Artificial intelligence learning may be applied to large datasets. Conclusions: Both objective and subjective assessments have their limitations. A balanced approach, combining both may provide the most complete and accurate picture.

  • Do We Need to Re‐Focus on Functional Female Urethral Disorders in Lower Urinary Tract Dysfunction? ICI‐RS 2024

    by Christopher J. Chermansky, Jeremy L. Ockrim, George Bou Kheir, Christopher R. Chapple, Rohna Kearney, Bogdan Toia, Roger R. Dmochowski, Alan J. Wein, Paul Abrams

    Aims: Insights into the role of the urethra in maintaining continence and in normal voiding have been provided with advances in imaging techniques. Also, functional urethral testing is used to understand which treatments are optimal for women with functional bladder outlet obstruction (BOO), but which testing is better for which treatment? This review aims to describe our current understanding of female urethral function and dysfunction and to provide future research directions for treating functional female urethral disorders.Materials and Methods: This is a consensus report of the proceedings of a research proposal discussed at the annual International Consultation on Incontinence‐Research Society (ICI‐RS), 6th–8th June 2024 (Bristol, UK): “Do we need to re‐focus on functional female urethral disorders in lower urinary tract dysfunction? ICI‐RS 2024”.Results: Regarding female urethral nomenclature, it was agreed that the same terminology should be used in the orientation of the female urethra as in the male. Also, functional MRI and computer modeling could aid further understanding of urethral function in women with voiding dysfunction and OAB symptoms. As for functional urethral assessment, options include video‐urodynamics with leak point pressure (LPP) testing, urethral pressure profilometry (UPP), and striated urethral sphincter electromyography (EMG). Future testing may include the use of modalities (borrowed from cardiologic assessment of vascular structures such as resistive measures obtained with ultrasound) for the purpose of assessing urethral closure. UPP testing has limitations in measurement and reproducibility in assessing urethral pressure. Urethral sphincter EMG is difficult to perform and reproduce. LPP also has limitations related to testing and to patient effort, in addition to being influenced by factors such as bladder volume and compliance. When performing urethral surgery, it is imperative to dissect in tissue planes that preserve urethral function. Regarding therapeutic modalities for the treatment of functional female urethral dysfunction, conservative management includes pelvic floor muscle training with or without biofeedback, electrical stimulation, and extracorporeal magnetic stimulation. Furthermore, there was a robust discussion on the use of cognitive‐behavioral therapy to address psychological comorbidities, thereby improving female LUTD. The evidence supporting long‐term pharmacologic treatment of female urethral LUTD remains scarce. As for invasive management options, the evidence supporting the use of botulinum toxin in female LUTD is limited. Finally, the very existence of BNO and the validity of its diagnosis was discussed. Furthermore, bladder neck incision as a treatment of BNO was debated, and the indications for this procedure include a therapeutic decision balancing benefit to complications.Conclusion: Improving the treatment of female functional storage and voiding disorders depends on optimal urethral function assessment. Functional MRI to better understand urethral function, expanding the use of UPP testing, LPP testing, and emerging modalities while maintaining urethral function during female urethral surgery, and addressing psychological comorbidities whilst pursuing both conservative and invasive options (for refractory symptoms) are all important considerations in treating functional female urethral disorders.


  • Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy

    by Elsie E. Mensah, Bogdan Toia, Linh Nguyen, Rizwan Hamid, Mahreen Pakzad, Jeremy L. Ockrim, Roger Walker, Tamsin J. Greenwell, Tharani Nitkunan, Davendra Sharma, et al.

    Aims: To determine the bleeding risk in patients taking anticoagulants (AC) and antiplatelets (AP) before onabotulinumtoxinA (BoNT‐A) injections and improve peri‐operative decision making and counseling.Methods: We performed a retrospective review of patients having intravesical BoNT‐A in three teaching hospitals from January 2016 to July 2018. Demographic data, indication for intravesical BoNT‐A injection, and side‐effects of significant bleeding requiring intervention were recorded.Results: Five hundred and thirty‐two patients had intravesical BoNT‐A injections during this time. Sixty‐three patients of mean age 69 years (range 19–89) had a total of 114 separate rounds of BoNT‐A injections whilst on treatment dose AC/AP therapy. Of the 63, there were 33 males, with 46 having idiopatic detrusor overactivity and 17 with neurogenic detrusor overactivity. Each patient had between 1 and 7 repeat injections during the studied period. AC/AP use across the 114 episodes included; aspirin 44, clopidogrel 37, warfarin 19, and NOAC (novel/non‐vitamin K oral anticoagulant) 14. Patients on warfarin who had point of care testing all had international normalized ratio less than 3. BoNT‐A dose varied from 100U to 300U—modal dosage was 200U.1/114(0.88%) injection episodes resulted in postinjection hematuria requiring overnight admission. This resolved spontaneously, with an overnight catheter. This patient was on rivaroxaban and had 300U of BoNT‐A injected through 20 sites, on a background of previous prostate radiotherapy and self‐catheterization.Conclusions: Continuation of AP/AC therapy during intravesical BoNT‐A injection treatment appears to be safe—with a 0.88% rate of spontaneously resolving hematuria.


  • Functional outcomes of vaginal surgery for urethral extrusion of mid-urethral tape in women

    by Bogdan Toia, Stephen Unterberg, Neha Sihra, Mahreen Pakzad, Rizwan Hamid, Jeremy L. Ockrim, Tamsin J. Greenwell

    Introduction and hypothesis We aim to determine the presentation of and immediate and longer-term outcomes of vaginal surgical excision of urethral extrusion of mid-urethral tape (MUT). Methods We performed a retrospective analysis of all patients with urethral extrusion of MUT having vaginal surgical excision between 2007 and 2018. The MUT was removed either partially (via vaginal approach) or completely (via combined vaginal and laparoscopic approach). Functional outcomes and any re-interventions are described. Results Thirty-four patients of median age 53 (range 34–82) years were identified. Preoperative symptomatic recurrent/persistent urinary incontinence was present in 29/34(85%) with 24/34(71%) women having recurrent/persistent stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (s-MUI) on urodynamics. Vaginal surgical excision was performed alone in 33/34(97%) women and in combination with laparoscopic removal of abdominopelvic MUT in 1/34(3%) woman. In the longer term vaginal/urethral pain resolved or improved in all 15/15(100%) patients presenting with this complaint whilst patient reported poor flow resolved in 8/9 (89%) women. Twenty-eight of 34 women (82%) had persistent/recurrent SUI or s-MUI following MUT excision. Twenty-four of 34 women (71%) had further SUI surgery with cure or improvement of SUI in 20/24 (83%) patients. Conclusions The outcome of vaginal surgical excision of the MUT was cure or improvement of pain in 100% and resolution of poor flow in 89% women. Recurrent/persistent SUI or s-MUI was present in 82% following removal as compared to 71% women prior to removal. Of the 71% of women electing to have further surgery for recurrent/persistent SUI/s-MUI, 83% were dry or improved afterwards.


  • Bulkamid® injection in men: Cadaver study of operative technique and putative mechanism of action

    by Bogdan Toia, Eabhann O’cOnnor, Tamsin J Greenwell, Jeremy L Ockrim, Eskinder Solomon

    Objective: Post-prostatectomy incontinence (PPI) is relatively common and of variable degree. Treatment of small-volume persistent PPI with a male sling or an artificial urinary sphincter is overly invasive, and the concept of intraurethral injection is very appealing in this situation. Bulkamid® is a nanoparticulate polyacrylamide and water polymer gel which is being used successfully in female stress urinary incontinence. We assessed the feasibility and effects of a four-point intraurethral technique on maximum urethral pressure (MUP) in male cadavers. Methods: Urethral pressure profile (UPP) was measured twice on two male fresh-frozen cadaver models before and after a four-point injection of 2 mL of Bulkamid® intraurethrally at the level of the sphincter in 0.5 mL aliquots using a 21Ch cystoscope with a 12° telescope and a 23G needle. Results: A clear UPP trace was recordable in both cadavers. The mean MUP at baseline was 38 cm H2O, and the mean MUP following Bulkamid® intraurethral injection increased to 55 cm H2O. Conclusions: Bulkamid® intraurethral injection in male cadavers is a simple technique that increases MUP. This increase in MUP may allow for treatment of low-volume PPI in men following prostate cancer treatment and warrants further study in the clinical situation. Level of evidence: Level 4.


  • A comparison of flow rate curve shape and video-urodynamic findings in women with lower urinary tract symptoms: can flow rate curve shape predict female bladder outflow obstruction or detrusor underactivity?

    by Huriye Kocadag, Bogdan Toia, Richard Axell, Habiba Yasmin, Mahreen H. Pakzad, Rizwan Hamid, Tamsin J. Greenwell, Jeremy L. Ockrim

    Purpose To establish the correlation between flow rate curve shape and video-urodynamic findings in women with lower urinary tract symptoms (LUTS). Methods A retrospective review of consecutive women with LUTS who performed a free flow study immediately before undergoing video-urodynamic investigations over a 28-month period. Flow rate curve shape and video-urodynamic parameters were analysed. Free flow curves were defined into five categories: bell-shaped, prolonged, fluctuating, intermittent or plateau. Women who voided less than 150 ml on the free flow study were excluded from the analysis. Results A total of 250 women with LUTS, with a mean age 48 years (range 18–83), were included. Bell-shaped tracings excluded obstruction in 89%. Prolonged flow rate curves diagnosed obstruction in 62% and detrusor underactivity in 8%. Fluctuating and intermittent flow rate curves were associated with urodynamic obstruction in 37 and 39%, respectively, and detrusor underactivity in 25 and 29%, respectively. A plateau flow rate curve was indicative of urodynamic obstruction in all three cases observed. Conclusion Flow rate curve patterns can be suggestive of urodynamic diagnoses. Women without a prolonged void and bell-shaped traces had normal voiding urodynamics in 76% of cases, and the majority could be managed without invasive investigations. Patients with fluctuating and intermittent flow rate curves demonstrate a spectrum of urodynamic diagnoses with a third of cases having obstruction and a third of cases having detrusor underactivity. Plateau flow rate curve patterns are associated with urethral obstruction.


  • The efficacy of onabotulinumtoxinA in patients with previous failed augmentation cystoplasty: Cohort series and literature review

    by Bogdan Toia, Mahreen H. Pakzad, Rizwan Hamid, Dan N Wood, Tamsin J. Greenwell, Jeremy L. Ockrim

    Aims: To investigate the role of onabotulinumtoxinA (BTX‐A) injections in patients with failed augmentation cystoplasty for neuropathic or idiopathic detrusor overactivity (NDO or IDO).Methods: A retrospective review of all cystoplasty patients who underwent onabotulinumtoxinA injection at a tertiary center between 2008 and 2019 was performed. Details including indications and time from cystoplasty, video‐urodynamic parameters, onabotulinumtoxinA dose, and clinical outcomes were analyzed. Telephone interview was performed for patients that requested repeat onabotulinumtoxinA injections. The interview included a modified PGIC7 and UDI6 questionnaires. A positive clinical response was considered improvement of overactive symptoms sufficient to merit repeat onabotulinumtoxinA injection and a modified PGIC7 of four or above.Results: Thirty patients were identified (11 men and 19 women). The indications for augmentation were IDO (n = 18) or NDO (n = 12). Mean age at the time of cystoplasty was 42 years (range, 10‐61). Interval between cystoplasty and initial onabotulinumtoxinA was 98 months (range, 3‐271). Video‐urodynamics before onabotulinumtoxinA revealed low compliance in 13 patients, DO in 22 patients, and combined low compliance/DO in 10. The median maximum cystometric bladder capacity was 338 mL (range, 77‐570 mL). Thirteen patients responded to onabotulinumtoxinA injections. Higher peak DO pressure was associated with a significantly higher chance that the patient would experience benefit from the injections P = .026). The patients that responded to onabotulinumtoxin A underwent a total of 115 procedures (mean, 8.8 injections) over a mean 88 months (range, 20‐157 months).Conclusions: Forty‐three percent of patients responded well to intra‐detrusor onabotulinumtoxinA injections. This avoided the need for more invasive surgery and had a positive impact on their quality of life.


  • Open Access

    Is pre-operative urodynamic bladder function the true predictor of outcome of male sling for post prostatectomy incontinence?

    by Bogdan Toia, Lap Yan Leung, Raveen Saigal, Eskinder Solomon, Sachin Malde, Claire Taylor, Arun Sahai, Rizwan Hamid, Jai H. Seth, Davendra Sharma, et al.

    Purpose: To investigate pre-operative urodynamic parameters in male sling patients to ascertain whether this might better predict surgical outcomes and facilitate patient selection. Methods: We performed a retrospective, case notes and video-urodynamics, review of men who underwent AdVanceXP male sling in three London hospitals between 2012 and 2019. Urodynamics were performed in all centres, while retrograde leak point pressure (RLPP) was performed in one centre. Results: Successful outcome was seen in 99/130 (76%) of men who required one pad or less per day. The dry rate was 51%. Pad usage was linked to worse surgical outcomes, mean 2.6 (range 1–6.5) for success vs 3.6 (range 1–10) although the ranges were wide (p = 0.002). 24 h pad weight also reached statistical significance (p = 0.05), with a mean of 181 g for success group versus 475 g for the non-successful group. The incidence of DO in the non-successful group was significantly higher than in successful group (55% versus 29%, p = 0.0009). Bladder capacity less than 250 ml was also associated with worse outcomes (p = 0.003). Reduced compliance was not correlated with outcomes (31% for success groups vs 45% for non-successful group, p = 0.15). Preoperative RLPP was performed in 60/130 patients but did not independently reach statistical significance (p = 0.25). Conclusion: Urodynamic parameters related to bladder function—detrusor overactivity and reduced maximum cystometric capacity predict male sling outcomes and may help in patient selection for male sling (or sphincter) surgery; whereas urodynamic parameters of sphincter incompetency (RLPP) were not predictive. Further larger scale studies are required to confirm these findings.